Skip to main content
Smart Investors Daily
AG

NASDAQ · AGEN

Agenus Inc.

Healthcare · Biotechnology

$6.29

Down-$0.44 (-6.54%)

Updated Nov 17, 2026, 2:08 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
113.25M
P/E ratio
-3.02
Dividend yield
0.00%
52-week range
$2.85 – $10.31
Volume
568.27K
Avg. volume
654.19K

Price performance · AGEN

AGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

AGEN closed at $6.29 after 21 trading sessions, up 1.78% for the selected period.

Last close
$6.29
Period change
+1.78%
Period low
$6.16
Period high
$7.22
Daily close
View OHLC price history
AGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$6.60$6.6648$6.245$6.29568.27K
Nov 13, 2026$6.97$6.97$6.50$6.73465.15K
Nov 12, 2026$7.07$7.085$6.775$6.87499.05K
Nov 11, 2026$7.13$7.29$7.02$7.22430.51K
Nov 10, 2026$7.10$7.13$6.635$7.02691.63K
Nov 9, 2026$7.32$7.65$7.11$7.15840.87K
Nov 6, 2026$6.54$7.20$6.3715$7.15873.56K
Nov 5, 2026$6.81$6.93$6.11$6.441.33M
Nov 4, 2026$6.99$7.06$6.85$6.97729.96K
Nov 3, 2026$6.59$6.86$6.5001$6.67499.04K
Nov 2, 2026$6.85$6.855$6.43$6.53595.56K
Oct 30, 2026$6.87$7.09$6.69$6.84564.49K
Oct 29, 2026$7.13$7.30$6.942$7.09625.39K
Oct 28, 2026$6.51$7.14$6.47$7.13744.3K
Oct 27, 2026$6.13$6.675$6.11$6.65839.02K
Oct 26, 2026$6.49$6.50$6.14$6.16687.89K
Oct 23, 2026$6.36$6.50$6.16$6.33510.51K
Oct 22, 2026$6.32$6.53$6.2364$6.51553.95K
Oct 21, 2026$6.43$6.54$6.31$6.40789.68K
Oct 20, 2026$6.10$6.58$6.05$6.42827.18K
Oct 19, 2026$6.13$6.30$6.055$6.18734.96K

Latest AGEN news

The latest Smart Investors Daily articles mentioning AGEN.

AGEN research

Overview

Company profile and research snapshot.

Company profile

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.33
Implied upside
—
Analysts
9
AGEN recent ratings
DateFirmRatingTarget
Nov 9, 2026B. Riley SecuritiesBuy—
Oct 26, 2026Chardan CapitalBuy—
Oct 22, 2026Chardan CapitalBuy—
Oct 5, 2026Chardan CapitalBuy—
Sep 28, 2026Rodman & RenshawBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

LEXINGTON, Mass., November 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were pres

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.